<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790023</url>
  </required_header>
  <id_info>
    <org_study_id>060-622</org_study_id>
    <nct_id>NCT00790023</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis</brief_title>
  <official_title>A Randomized, Multicenter, Double Blind, Placebo Controlled, Parallel Group, Phase III Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg)
      once daily compared to placebo in subjects with SAR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, placebo controlled, parallel group, multicenter study to
      demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg)
      once daily compared to placebo in subjects with SAR. This study was previously posted by
      Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and
      in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Averaged Over the Two-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM iTNSS Averaged Over the Two-week Treatment Period.</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM rTOSS Averaged Over the Two-week Treatment Period in Participants With a Baseline rTOSS &gt;= 5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM rTNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM rTNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM iTNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM iTNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject Reported AM and PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM rNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM rNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM rNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM iNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM iNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM iNSS Averaged Over the Two Week Treatment Period</measure>
    <time_frame>Week 0-2</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported and AM and PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overall Score of the Rhinoconjunctivitis Quality of Life Questionnaire With Standard Activities (RQLQ(S)) in Participants With a Baseline Overall Score &gt;= 3.0</measure>
    <time_frame>Week 0-2</time_frame>
    <description>The RQLQ(S) in impaired subjects (baseline RQLQ[S] score ≥3.0) at baseline and end of week 2. It consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Improvement in Instantaneous Total Nasal Symptoms Scores (iTNSS)</measure>
    <time_frame>Baseline and up to 36 hours</time_frame>
    <description>Onset of nasal improvement was defined as the first assessment at which iTNSS for active treatment demonstrated an improvement over placebo from baseline.
TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent, 1 = mild, 2 = moderate, 3 = severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and 12 reflecting more severe symptoms). Instaneous measures these symptoms over the previous 10 minute time interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Improvement in Instantaneous Total Ocular Symptoms Scores (iTOSS) in Subjects With Baseline iTOSS ≥5.0</measure>
    <time_frame>Baseline and up to 48 hours</time_frame>
    <description>Onset of improvement iTOSS was defined as the first assessment at which iTOSSS for active treatment demonstrated an improvement over placebo from baseline. TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximal Effect as Measured by Change From Baseline in the Average AM and PM Reflective Total Nasal Symptoms Scores (rTNSS)</measure>
    <time_frame>Week 0-2</time_frame>
    <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">707</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>80 mcg Ciclesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mcg Ciclesonide once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>160 mcg Ciclesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 mcg Ciclesonide once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mcg Ciclesonide</intervention_name>
    <description>80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)</description>
    <arm_group_label>80 mcg Ciclesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>160 mcg Ciclesonide</intervention_name>
    <description>160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)</description>
    <arm_group_label>160 mcg Ciclesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo HFA Inhaler once daily (one actuation per nostril)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give written informed consent, including privacy authorization as well as adherence to
             concomitant medication withholding periods, prior to participation.

          -  Male or female 12 years and older, as of the Screening Visit (Visit 1).

          -  Subject must be in general good health (defined as the absence of any clinically
             relevant abnormalities as determined by the Investigator) based on screening physical
             examination, medical history, and clinical laboratory values (Hematology, Chemistries
             and Urinalysis).

          -  A history of SAR to Mountain Cedar for a minimum of two years immediately preceding
             the study Screening Visit (Visit 1). The SAR must have been of sufficient severity to
             have required treatment (either continuous or intermittent) in the past and in the
             Investigator's judgment (through exposure to allergen) is expected to require
             treatment throughout the entire study period.

          -  A demonstrated sensitivity to Mountain Cedar known to induce SAR through a standard
             skin prick test administered at Visit 1 (screening). A positive test is defined as a
             wheal diameter at least 5 mm larger than the control wheal (normal saline) for the
             skin prick test.

          -  Subject, if female 65 years of age or younger, must have a negative serum pregnancy
             test (performed at Visit 1) prior to randomization at Visit 2. Women of childbearing
             potential (excluding females at least two years postmenopausal or surgically sterile)
             must sign the Women of Childbearing Potential Addendum to the informed consent form.
             Females of childbearing potential must be instructed to and agree to avoid pregnancy
             during the study and must use an acceptable method of birth control:

               1. An oral contraceptive, an intrauterine device (IUD), implantable contraceptive,
                  transdermal or injectable contraceptive for at least 1 month prior to entering
                  the study and will continue its use throughout the study and for thirty days
                  following study participation.

               2. Barrier method of contraception, eg, condom and/or diaphragm with spermicide
                  while participating in the study.

               3. Abstinence.

          -  Subject or parent/guardian must possess an educational level and degree of
             understanding of English that enables them to communicate suitably with the
             Investigator and study coordinator as well as accurately complete both the AR diary
             and RQLQ(S).

        Exclusion Criteria:

          -  Female subject who is pregnant or lactating.

          -  History of physical findings of nasal pathology, including nasal polyps or other
             clinically significant respiratory tract malformations; recent nasal biopsy; nasal
             trauma; nasal ulcers or perforations; or surgery and atrophic rhinitis or rhinitis
             medicamentosa (all within the last 60 days prior to the Screening Visit).

          -  Participation in any investigational drug trial within the 30 days preceding the
             Screening Visit (Visit 1) or planned participation in another investigational drug
             trial at any time during this trial.

          -  A known hypersensitivity to any corticosteroid or any of the excipients in the
             formulation of ciclesonide.

          -  History of a respiratory infection or disorder [including, but not limited to
             bronchitis, pneumonia, chronic sinusitis, influenza, severe acute respiratory syndrome
             (SARS)] within the 14 days preceding the Screening Visit (Visit 1).

          -  History of alcohol or drug abuse (or a positive urine drug screen at Visit 1) within
             two years preceding the Screening Visit.

          -  History of a positive test for HIV, hepatitis B or hepatitis C.

          -  Plans to travel outside the study area (the known pollen area for the investigative
             site) for more than 24 hours during the Run in period.

          -  Plans to travel outside the study area (the known pollen area for the investigative
             site) for 2 or more consecutive days between Randomization Visit (Visit 3) and the
             final Treatment Visit (Visit 5).

          -  Active asthma requiring treatment with inhaled or systemic corticosteroids and/or
             routine use of beta agonists and any controller drugs (e.g., theophylline, leukotriene
             antagonists, etc.); intermittent use (less than or equal to 3 uses per week) of
             inhaled short acting beta-agonists is acceptable.

          -  Use of any prohibited concomitant medications within the prescribed (per protocol)
             time period prior to the Screening Visit and expected use during treatment period.

          -  Use of antibiotic therapy for acute conditions within 14 days prior to the Screening
             Visit. Low doses of antibiotics taken for prophylaxis are permitted if the therapy was
             started prior to the Screening Visit and is expected to continue throughout the trial.

          -  Initiation of immunotherapy during the study period or dose escalation during the
             study period. However, initiation of immunotherapy 90 days or more prior to the
             Screening Visit and use of a stable (maintenance) dose (30 days or more) may be
             considered for inclusion.

          -  Previous participation in an intranasal ciclesonide HFA nasal aerosol study.

          -  Non-vaccinated exposure to or active infection with, chickenpox or measles within the
             21 days preceding the Screening Visit.

          -  Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone or
             equivalent within 30 days prior to Visit 2; use of a topical hydrocortisone or
             equivalent in any concentration covering greater than 20% of the body surface; or
             presence of an underlying condition (as judged by the investigator) that can
             reasonably be expected to require treatment with such preparations during the course
             of the study.

          -  Initiation of pimecrolimus cream 1% or greater or tacrolimus ointment 0.03% or greater
             during the study period or planned dose escalation during the study period. However,
             initiation of these creams/ointments 30 days or more prior to the Visit 1 and use of a
             stable (maintenance) dose during the study period may be considered for inclusion.

          -  Study participation by clinical investigator site employees and/or their immediate
             relatives.

          -  Study participation by more than one subject from the same household at the same time.

          -  Have any of the following conditions that are judged by the investigator to be
             clinically significant and/or affect the subject's ability to participate in the
             clinical trial: impaired hepatic function including alcohol-related liver disease or
             cirrhosis;

               -  history of ocular disturbances e.g. glaucoma or posterior subcapsular cataracts;

               -  any systemic infection;

               -  hematological, hepatic, renal, endocrine (except for controlled diabetes mellitus
                  or postmenopausal symptoms or hypothyroidism);

               -  gastrointestinal disease;

               -  malignancy (excluding basal cell carcinoma);

               -  current neuropsychological condition with or without drug therapy.

          -  Any condition that, in the judgment of the investigator, would preclude the subject
             from completing the protocol with capture of the assessments as written.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <zip>78028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ratner P, Jacobs R, Mohar D, Huang H, Desai SY, Hinkle J. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2010 Dec;105(6):471-9. doi: 10.1016/j.anai.2010.09.024.</citation>
    <PMID>21130386</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>February 15, 2012</results_first_submitted>
  <results_first_submitted_qc>May 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2012</results_first_posted>
  <disposition_first_submitted>August 7, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 7, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 11, 2009</disposition_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>80 mcg Ciclesonide</title>
          <description>80 mcg Ciclesonide once daily</description>
        </group>
        <group group_id="P2">
          <title>160 mcg Ciclesonide</title>
          <description>160 mcg Ciclesonide once daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="235"/>
                <participants group_id="P3" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>80 mcg Ciclesonide</title>
          <description>80 mcg Ciclesonide once daily</description>
        </group>
        <group group_id="B2">
          <title>160 mcg Ciclesonide</title>
          <description>160 mcg Ciclesonide once daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="237"/>
            <count group_id="B2" value="235"/>
            <count group_id="B3" value="235"/>
            <count group_id="B4" value="707"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="12.7"/>
                    <measurement group_id="B2" value="42.1" spread="12.9"/>
                    <measurement group_id="B3" value="42.2" spread="13.9"/>
                    <measurement group_id="B4" value="41.8" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="220"/>
                    <measurement group_id="B4" value="658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline reflective total nasal symptom score (rTNSS)</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe. Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.36" spread="1.76"/>
                    <measurement group_id="B2" value="9.47" spread="1.68"/>
                    <measurement group_id="B3" value="9.08" spread="1.85"/>
                    <measurement group_id="B4" value="9.31" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.28" spread="1.92"/>
                    <measurement group_id="B2" value="9.44" spread="1.80"/>
                    <measurement group_id="B3" value="9.13" spread="1.87"/>
                    <measurement group_id="B4" value="9.28" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.32" spread="1.77"/>
                    <measurement group_id="B2" value="9.46" spread="1.67"/>
                    <measurement group_id="B3" value="9.10" spread="1.80"/>
                    <measurement group_id="B4" value="9.29" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline instantaneous total nasal symptom score (iTNSS)</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe. Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.83" spread="2.03"/>
                    <measurement group_id="B2" value="9.05" spread="2.02"/>
                    <measurement group_id="B3" value="8.74" spread="2.05"/>
                    <measurement group_id="B4" value="8.87" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.53" spread="2.22"/>
                    <measurement group_id="B2" value="8.82" spread="2.14"/>
                    <measurement group_id="B3" value="8.48" spread="2.21"/>
                    <measurement group_id="B4" value="8.61" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.68" spread="2.05"/>
                    <measurement group_id="B2" value="8.94" spread="2.00"/>
                    <measurement group_id="B3" value="8.61" spread="2.06"/>
                    <measurement group_id="B4" value="8.74" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline reflective total ocular symptom score (rTOSS) in subjects with (rTOSS) ≥5.0</title>
          <description>Total Ocular Symptom Score(TOSS) is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.89" spread="1.27"/>
                    <measurement group_id="B2" value="6.98" spread="1.22"/>
                    <measurement group_id="B3" value="6.95" spread="1.33"/>
                    <measurement group_id="B4" value="6.94" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.90" spread="1.24"/>
                    <measurement group_id="B2" value="7.04" spread="1.13"/>
                    <measurement group_id="B3" value="6.96" spread="1.25"/>
                    <measurement group_id="B4" value="6.97" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.89" spread="1.19"/>
                    <measurement group_id="B2" value="7.01" spread="1.11"/>
                    <measurement group_id="B3" value="6.95" spread="1.23"/>
                    <measurement group_id="B4" value="6.95" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline instantaneous total ocular symptom score (iTOSS) in subjects with (iTOSS) ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.91" spread="1.19"/>
                    <measurement group_id="B2" value="7.04" spread="1.16"/>
                    <measurement group_id="B3" value="7.17" spread="1.19"/>
                    <measurement group_id="B4" value="7.03" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.67" spread="1.29"/>
                    <measurement group_id="B2" value="6.81" spread="1.24"/>
                    <measurement group_id="B3" value="6.86" spread="1.35"/>
                    <measurement group_id="B4" value="6.78" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.79" spread="1.14"/>
                    <measurement group_id="B2" value="6.92" spread="1.11"/>
                    <measurement group_id="B3" value="7.01" spread="1.19"/>
                    <measurement group_id="B4" value="6.90" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline reflective nasal symptom score (rNSS)</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.02" spread="0.73"/>
                    <measurement group_id="B2" value="2.11" spread="0.62"/>
                    <measurement group_id="B3" value="2.00" spread="0.71"/>
                    <measurement group_id="B4" value="2.04" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.44" spread="0.55"/>
                    <measurement group_id="B2" value="2.41" spread="0.56"/>
                    <measurement group_id="B3" value="2.37" spread="0.57"/>
                    <measurement group_id="B4" value="2.41" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.33" spread="0.59"/>
                    <measurement group_id="B2" value="2.35" spread="0.54"/>
                    <measurement group_id="B3" value="2.22" spread="0.61"/>
                    <measurement group_id="B4" value="2.30" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.57" spread="0.43"/>
                    <measurement group_id="B2" value="2.60" spread="0.43"/>
                    <measurement group_id="B3" value="2.48" spread="0.50"/>
                    <measurement group_id="B4" value="2.55" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.08" spread="0.69"/>
                    <measurement group_id="B2" value="2.17" spread="0.61"/>
                    <measurement group_id="B3" value="2.11" spread="0.64"/>
                    <measurement group_id="B4" value="2.12" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.39" spread="0.59"/>
                    <measurement group_id="B2" value="2.39" spread="0.58"/>
                    <measurement group_id="B3" value="2.35" spread="0.58"/>
                    <measurement group_id="B4" value="2.38" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.32" spread="0.61"/>
                    <measurement group_id="B2" value="2.36" spread="0.54"/>
                    <measurement group_id="B3" value="2.25" spread="0.62"/>
                    <measurement group_id="B4" value="2.31" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.49" spread="0.51"/>
                    <measurement group_id="B2" value="2.52" spread="0.48"/>
                    <measurement group_id="B3" value="2.42" spread="0.53"/>
                    <measurement group_id="B4" value="2.48" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.05" spread="0.69"/>
                    <measurement group_id="B2" value="2.14" spread="0.59"/>
                    <measurement group_id="B3" value="2.05" spread="0.65"/>
                    <measurement group_id="B4" value="2.08" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.41" spread="0.55"/>
                    <measurement group_id="B2" value="2.40" spread="0.55"/>
                    <measurement group_id="B3" value="2.36" spread="0.56"/>
                    <measurement group_id="B4" value="2.39" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.32" spread="0.58"/>
                    <measurement group_id="B2" value="2.36" spread="0.53"/>
                    <measurement group_id="B3" value="2.23" spread="0.59"/>
                    <measurement group_id="B4" value="2.30" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.53" spread="0.44"/>
                    <measurement group_id="B2" value="2.56" spread="0.43"/>
                    <measurement group_id="B3" value="2.45" spread="0.50"/>
                    <measurement group_id="B4" value="2.51" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline instantaneous nasal symptom score (iNSS)</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.72" spread="0.91"/>
                    <measurement group_id="B2" value="1.83" spread="0.83"/>
                    <measurement group_id="B3" value="1.77" spread="0.89"/>
                    <measurement group_id="B4" value="1.77" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.35" spread="0.59"/>
                    <measurement group_id="B2" value="2.35" spread="0.64"/>
                    <measurement group_id="B3" value="2.32" spread="0.61"/>
                    <measurement group_id="B4" value="2.34" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.26" spread="0.62"/>
                    <measurement group_id="B2" value="2.30" spread="0.61"/>
                    <measurement group_id="B3" value="2.18" spread="0.61"/>
                    <measurement group_id="B4" value="2.24" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.50" spread="0.48"/>
                    <measurement group_id="B2" value="2.58" spread="0.48"/>
                    <measurement group_id="B3" value="2.47" spread="0.52"/>
                    <measurement group_id="B4" value="2.52" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.77" spread="0.85"/>
                    <measurement group_id="B2" value="1.92" spread="0.79"/>
                    <measurement group_id="B3" value="1.81" spread="0.86"/>
                    <measurement group_id="B4" value="1.83" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.23" spread="0.66"/>
                    <measurement group_id="B2" value="2.26" spread="0.66"/>
                    <measurement group_id="B3" value="2.23" spread="0.63"/>
                    <measurement group_id="B4" value="2.24" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.17" spread="0.67"/>
                    <measurement group_id="B2" value="2.24" spread="0.64"/>
                    <measurement group_id="B3" value="2.11" spread="0.66"/>
                    <measurement group_id="B4" value="2.17" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.36" spread="0.57"/>
                    <measurement group_id="B2" value="2.39" spread="0.53"/>
                    <measurement group_id="B3" value="2.33" spread="0.57"/>
                    <measurement group_id="B4" value="2.36" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.75" spread="0.86"/>
                    <measurement group_id="B2" value="1.88" spread="0.78"/>
                    <measurement group_id="B3" value="1.79" spread="0.85"/>
                    <measurement group_id="B4" value="1.80" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.29" spread="0.60"/>
                    <measurement group_id="B2" value="2.30" spread="0.62"/>
                    <measurement group_id="B3" value="2.27" spread="0.59"/>
                    <measurement group_id="B4" value="2.29" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.21" spread="0.62"/>
                    <measurement group_id="B2" value="2.27" spread="0.60"/>
                    <measurement group_id="B3" value="2.15" spread="0.61"/>
                    <measurement group_id="B4" value="2.21" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.43" spread="0.49"/>
                    <measurement group_id="B2" value="2.49" spread="0.47"/>
                    <measurement group_id="B3" value="2.40" spread="0.52"/>
                    <measurement group_id="B4" value="2.44" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline individual reflective ocular symptom score (rOSS) in subjects with (rTOSS) ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective OSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms).</description>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.48" spread="0.42"/>
                    <measurement group_id="B2" value="2.45" spread="0.50"/>
                    <measurement group_id="B3" value="2.42" spread="0.49"/>
                    <measurement group_id="B4" value="2.45" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.14" spread="0.59"/>
                    <measurement group_id="B2" value="2.26" spread="0.53"/>
                    <measurement group_id="B3" value="2.25" spread="0.55"/>
                    <measurement group_id="B4" value="2.22" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.26" spread="0.52"/>
                    <measurement group_id="B2" value="2.27" spread="0.48"/>
                    <measurement group_id="B3" value="2.27" spread="0.53"/>
                    <measurement group_id="B4" value="2.27" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Itching of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.47" spread="0.40"/>
                    <measurement group_id="B2" value="2.48" spread="0.43"/>
                    <measurement group_id="B3" value="2.42" spread="0.45"/>
                    <measurement group_id="B4" value="2.46" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.15" spread="0.57"/>
                    <measurement group_id="B2" value="2.25" spread="0.50"/>
                    <measurement group_id="B3" value="2.28" spread="0.55"/>
                    <measurement group_id="B4" value="2.22" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.28" spread="0.50"/>
                    <measurement group_id="B2" value="2.31" spread="0.46"/>
                    <measurement group_id="B3" value="2.26" spread="0.50"/>
                    <measurement group_id="B4" value="2.28" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.48" spread="0.39"/>
                    <measurement group_id="B2" value="2.47" spread="0.44"/>
                    <measurement group_id="B3" value="2.42" spread="0.45"/>
                    <measurement group_id="B4" value="2.46" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.14" spread="0.56"/>
                    <measurement group_id="B2" value="2.25" spread="0.50"/>
                    <measurement group_id="B3" value="2.27" spread="0.53"/>
                    <measurement group_id="B4" value="2.22" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.27" spread="0.48"/>
                    <measurement group_id="B2" value="2.29" spread="0.44"/>
                    <measurement group_id="B3" value="2.26" spread="0.49"/>
                    <measurement group_id="B4" value="2.27" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline individual instantaneous ocular symtom score (iOSS) in subjects with (iTOSS) ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. rTOSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms).</description>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AM Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.44" spread="0.44"/>
                    <measurement group_id="B2" value="2.44" spread="0.46"/>
                    <measurement group_id="B3" value="2.48" spread="0.45"/>
                    <measurement group_id="B4" value="2.45" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.22" spread="0.56"/>
                    <measurement group_id="B2" value="2.32" spread="0.51"/>
                    <measurement group_id="B3" value="2.36" spread="0.52"/>
                    <measurement group_id="B4" value="2.30" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.25" spread="0.50"/>
                    <measurement group_id="B2" value="2.27" spread="0.48"/>
                    <measurement group_id="B3" value="2.33" spread="0.54"/>
                    <measurement group_id="B4" value="2.28" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.38" spread="0.41"/>
                    <measurement group_id="B2" value="2.40" spread="0.47"/>
                    <measurement group_id="B3" value="2.39" spread="0.49"/>
                    <measurement group_id="B4" value="2.39" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.12" spread="0.58"/>
                    <measurement group_id="B2" value="2.22" spread="0.52"/>
                    <measurement group_id="B3" value="2.28" spread="0.55"/>
                    <measurement group_id="B4" value="2.20" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PM Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.17" spread="0.52"/>
                    <measurement group_id="B2" value="2.19" spread="0.49"/>
                    <measurement group_id="B3" value="2.19" spread="0.56"/>
                    <measurement group_id="B4" value="2.18" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.41" spread="0.38"/>
                    <measurement group_id="B2" value="2.42" spread="0.43"/>
                    <measurement group_id="B3" value="2.43" spread="0.45"/>
                    <measurement group_id="B4" value="2.42" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.17" spread="0.54"/>
                    <measurement group_id="B2" value="2.27" spread="0.49"/>
                    <measurement group_id="B3" value="2.32" spread="0.51"/>
                    <measurement group_id="B4" value="2.25" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AM and PM Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.21" spread="0.47"/>
                    <measurement group_id="B2" value="2.23" spread="0.45"/>
                    <measurement group_id="B3" value="2.26" spread="0.51"/>
                    <measurement group_id="B4" value="2.23" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Instantaneous Total Ocular Symptoms Scores (iTOSS)] for Onset of Nasal Improvement</title>
          <description>Baseline is the last non-missing instantaneous AM assessment on or before Day 1. Onset of nasal improvement is defined as the first assessment at which instantaneous TNSS for active treatment demonstrates an improvement over placebo from baseline with one-sided p-value of &lt;= 0.025.</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.85" spread="1.72"/>
                    <measurement group_id="B2" value="7.02" spread="1.54"/>
                    <measurement group_id="B3" value="6.98" spread="1.60"/>
                    <measurement group_id="B4" value="6.95" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in subject with RQLQ(S) score ≥3.</title>
          <description>RQLQ(S)consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.52" spread="0.77"/>
                    <measurement group_id="B2" value="4.49" spread="0.78"/>
                    <measurement group_id="B3" value="4.43" spread="0.83"/>
                    <measurement group_id="B4" value="4.48" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Averaged Over the Two-week Treatment Period.</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Averaged Over the Two-week Treatment Period.</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to treat population.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="0.14"/>
                    <measurement group_id="O2" value="-1.59" spread="0.14"/>
                    <measurement group_id="O3" value="-0.51" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in primary outcome when compare active to placebo group. The alternative hypothesis is that there is a difference in primary outcome when compare active to placebo group. It was estimated that 200 subjects per group will provide at least 85% power to detect a difference between treatment groups of 0.7 in the change from baseline in rTNSS with a two-sided alpha level of 0.025.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value from primary outcome was adjusted at alpha=0.025.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in primary outcome when compare active to placebo group. The alternative hypothesis is that there is a difference in primary outcome when compare active to placebo group. It was estimated that 200 subjects per group will provide at least 85% power to detect a difference between treatment groups of 0.7 in the change from baseline in rTNSS with a two-sided alpha level of 0.025.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value from primary outcome was adjusted at alpha=0.025.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM iTNSS Averaged Over the Two-week Treatment Period.</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM iTNSS Averaged Over the Two-week Treatment Period.</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to treat population</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.13"/>
                    <measurement group_id="O2" value="-1.47" spread="0.13"/>
                    <measurement group_id="O3" value="-0.47" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM rTOSS Averaged Over the Two-week Treatment Period in Participants With a Baseline rTOSS &gt;= 5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to treat population. In participants with a baseline rTOSS &gt;= 5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM rTOSS Averaged Over the Two-week Treatment Period in Participants With a Baseline rTOSS &gt;= 5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Intent to treat population. In participants with a baseline rTOSS &gt;= 5.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="0.12"/>
                    <measurement group_id="O2" value="-1.05" spread="0.12"/>
                    <measurement group_id="O3" value="-0.44" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dmitrienko’s tree-structured gatekeeping method was used for multiple comparisons</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM rTNSS Averaged Over the Two Week Treatment Period</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM rTNSS Averaged Over the Two Week Treatment Period</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="0.14"/>
                    <measurement group_id="O2" value="-1.56" spread="0.14"/>
                    <measurement group_id="O3" value="-0.53" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM rTNSS Averaged Over the Two Week Treatment Period</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM rTNSS Averaged Over the Two Week Treatment Period</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="0.14"/>
                    <measurement group_id="O2" value="-1.60" spread="0.14"/>
                    <measurement group_id="O3" value="-0.51" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM iTNSS Averaged Over the Two Week Treatment Period</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM iTNSS Averaged Over the Two Week Treatment Period</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="0.13"/>
                    <measurement group_id="O2" value="-1.37" spread="0.14"/>
                    <measurement group_id="O3" value="-0.46" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM iTNSS Averaged Over the Two Week Treatment Period</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM iTNSS Averaged Over the Two Week Treatment Period</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.14"/>
                    <measurement group_id="O2" value="-1.55" spread="0.14"/>
                    <measurement group_id="O3" value="-0.49" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline rTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline rTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.12"/>
                    <measurement group_id="O2" value="-0.98" spread="0.12"/>
                    <measurement group_id="O3" value="-0.41" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline rTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM rTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TOSS symptom scores assess symptoms over the previous 12-hour time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline rTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.12"/>
                    <measurement group_id="O2" value="-1.11" spread="0.12"/>
                    <measurement group_id="O3" value="-0.47" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline iTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline iTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.13"/>
                    <measurement group_id="O2" value="-0.99" spread="0.13"/>
                    <measurement group_id="O3" value="-0.42" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline iTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline iTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="0.13"/>
                    <measurement group_id="O2" value="-1.16" spread="0.13"/>
                    <measurement group_id="O3" value="-0.36" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject Reported AM and PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
        <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline iTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject Reported AM and PM iTOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
          <description>TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval. Difference was calculated as week two treatment average – baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline iTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.12"/>
                    <measurement group_id="O2" value="-1.07" spread="0.12"/>
                    <measurement group_id="O3" value="-0.40" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM rNSS Averaged Over the Two Week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM rNSS Averaged Over the Two Week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.04"/>
                    <measurement group_id="O3" value="-0.12" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.04"/>
                    <measurement group_id="O2" value="-0.35" spread="0.04"/>
                    <measurement group_id="O3" value="-0.13" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.04"/>
                    <measurement group_id="O3" value="-0.17" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.03"/>
                    <measurement group_id="O2" value="-0.36" spread="0.03"/>
                    <measurement group_id="O3" value="-0.12" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM rNSS Averaged Over the Two Week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM rNSS Averaged Over the Two Week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.04"/>
                    <measurement group_id="O2" value="-0.46" spread="0.04"/>
                    <measurement group_id="O3" value="-0.13" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.04"/>
                    <measurement group_id="O2" value="-0.37" spread="0.04"/>
                    <measurement group_id="O3" value="-0.10" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.04"/>
                    <measurement group_id="O2" value="-0.44" spread="0.04"/>
                    <measurement group_id="O3" value="-0.17" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.04"/>
                    <measurement group_id="O2" value="-0.35" spread="0.04"/>
                    <measurement group_id="O3" value="-0.11" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM rNSS Averaged Over the Two Week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM rNSS Averaged Over the Two Week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.04"/>
                    <measurement group_id="O2" value="-0.44" spread="0.04"/>
                    <measurement group_id="O3" value="-0.12" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.04"/>
                    <measurement group_id="O2" value="-0.36" spread="0.04"/>
                    <measurement group_id="O3" value="-0.11" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.03"/>
                    <measurement group_id="O2" value="-0.36" spread="0.03"/>
                    <measurement group_id="O3" value="-0.11" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM iNSS Averaged Over the Two Week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM iNSS Averaged Over the Two Week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.04"/>
                    <measurement group_id="O2" value="-0.33" spread="0.04"/>
                    <measurement group_id="O3" value="-0.10" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.04"/>
                    <measurement group_id="O2" value="-0.29" spread="0.04"/>
                    <measurement group_id="O3" value="-0.09" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.04"/>
                    <measurement group_id="O2" value="-0.42" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.03"/>
                    <measurement group_id="O2" value="-0.33" spread="0.03"/>
                    <measurement group_id="O3" value="-0.11" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM iNSS Averaged Over the Two Week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM iNSS Averaged Over the Two Week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.04"/>
                    <measurement group_id="O2" value="-0.35" spread="0.04"/>
                    <measurement group_id="O3" value="-0.11" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.04"/>
                    <measurement group_id="O2" value="-0.44" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.04"/>
                    <measurement group_id="O2" value="-0.33" spread="0.04"/>
                    <measurement group_id="O3" value="-0.09" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM iNSS Averaged Over the Two Week Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM iNSS Averaged Over the Two Week Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 12-hour time interval. Baseline was the average of the AM and PM responses obtained during the run-in period up to 6 days prior to randomization. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.04"/>
                    <measurement group_id="O2" value="-0.38" spread="0.04"/>
                    <measurement group_id="O3" value="-0.12" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.04"/>
                    <measurement group_id="O2" value="-0.33" spread="0.04"/>
                    <measurement group_id="O3" value="-0.10" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.04"/>
                    <measurement group_id="O2" value="-0.43" spread="0.04"/>
                    <measurement group_id="O3" value="-0.15" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.03"/>
                    <measurement group_id="O2" value="-0.33" spread="0.03"/>
                    <measurement group_id="O3" value="-0.33" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline rTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline rTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.04"/>
                    <measurement group_id="O2" value="-0.33" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.04"/>
                    <measurement group_id="O2" value="-0.31" spread="0.04"/>
                    <measurement group_id="O3" value="-0.12" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.04"/>
                    <measurement group_id="O2" value="-0.35" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline rTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline rTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.04"/>
                    <measurement group_id="O2" value="-0.35" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.05"/>
                    <measurement group_id="O2" value="-0.34" spread="0.05"/>
                    <measurement group_id="O3" value="-0.16" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.04"/>
                    <measurement group_id="O2" value="-0.42" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported and AM and PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline rTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported and AM and PM rOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline rTOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Reflective OSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline rTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.04"/>
                    <measurement group_id="O2" value="-0.34" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.04"/>
                    <measurement group_id="O2" value="-0.32" spread="0.04"/>
                    <measurement group_id="O3" value="-0.14" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.04"/>
                    <measurement group_id="O2" value="-0.38" spread="0.04"/>
                    <measurement group_id="O3" value="-0.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline iTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline iTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.04"/>
                    <measurement group_id="O2" value="-0.32" spread="0.04"/>
                    <measurement group_id="O3" value="-0.17" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.05"/>
                    <measurement group_id="O2" value="-0.32" spread="0.05"/>
                    <measurement group_id="O3" value="-0.10" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.05"/>
                    <measurement group_id="O2" value="-0.35" spread="0.05"/>
                    <measurement group_id="O3" value="-0.13" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline iTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline iTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.04"/>
                    <measurement group_id="O2" value="-0.36" spread="0.04"/>
                    <measurement group_id="O3" value="-0.13" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.05"/>
                    <measurement group_id="O2" value="-0.38" spread="0.05"/>
                    <measurement group_id="O3" value="-0.13" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.05"/>
                    <measurement group_id="O2" value="-0.42" spread="0.05"/>
                    <measurement group_id="O3" value="-0.10" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
        <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In Subjects With Baseline iTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM iOSS Averaged Over the Two Week Treatment Period in Subjects With Baseline iTOSS ≥5.0</title>
          <description>OSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous OSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the two week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>In Subjects With Baseline iTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Itching Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.04"/>
                    <measurement group_id="O2" value="-0.34" spread="0.04"/>
                    <measurement group_id="O3" value="-0.15" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness of Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.04"/>
                    <measurement group_id="O2" value="-0.35" spread="0.04"/>
                    <measurement group_id="O3" value="-0.12" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tearing Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.04"/>
                    <measurement group_id="O2" value="-0.38" spread="0.04"/>
                    <measurement group_id="O3" value="-0.12" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overall Score of the Rhinoconjunctivitis Quality of Life Questionnaire With Standard Activities (RQLQ(S)) in Participants With a Baseline Overall Score &gt;= 3.0</title>
        <description>The RQLQ(S) in impaired subjects (baseline RQLQ[S] score ≥3.0) at baseline and end of week 2. It consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
        <time_frame>Week 0-2</time_frame>
        <population>In participants with a Baseline overall score &gt;= 3.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Score of the Rhinoconjunctivitis Quality of Life Questionnaire With Standard Activities (RQLQ(S)) in Participants With a Baseline Overall Score &gt;= 3.0</title>
          <description>The RQLQ(S) in impaired subjects (baseline RQLQ[S] score ≥3.0) at baseline and end of week 2. It consists of 28 questions, each question measured on a scale of 0-6 where a higher score indicates poor quality of life. Domains: Activities (questions 1-3), Sleep (questions 4-6), Non-Nose/Eye Symptoms (questions 7-13), Practical Problems (questions 14-16), Nasal Symptoms (questions 17-20), Eye Symptoms (questions 21-24), and Emotional (questions 25-28). The overall RQLQ(S) score was calculated as the average of the mean domain scores.</description>
          <population>In participants with a Baseline overall score &gt;= 3.0</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="0.10"/>
                    <measurement group_id="O2" value="-1.07" spread="0.10"/>
                    <measurement group_id="O3" value="-0.42" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Improvement in Instantaneous Total Nasal Symptoms Scores (iTNSS)</title>
        <description>Onset of nasal improvement was defined as the first assessment at which iTNSS for active treatment demonstrated an improvement over placebo from baseline.
TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent, 1 = mild, 2 = moderate, 3 = severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and 12 reflecting more severe symptoms). Instaneous measures these symptoms over the previous 10 minute time interval.</description>
        <time_frame>Baseline and up to 36 hours</time_frame>
        <population>Intent to Treat Population. Some participants excluded for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Onset of Improvement in Instantaneous Total Nasal Symptoms Scores (iTNSS)</title>
          <description>Onset of nasal improvement was defined as the first assessment at which iTNSS for active treatment demonstrated an improvement over placebo from baseline.
TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent, 1 = mild, 2 = moderate, 3 = severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and 12 reflecting more severe symptoms). Instaneous measures these symptoms over the previous 10 minute time interval.</description>
          <population>Intent to Treat Population. Some participants excluded for missing data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 4 Hours Postdose (n=237, 233, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.15"/>
                    <measurement group_id="O2" value="-0.79" spread="0.15"/>
                    <measurement group_id="O3" value="-0.84" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6 Hours Postdose (n=235, 234, 231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.16"/>
                    <measurement group_id="O2" value="-1.36" spread="0.16"/>
                    <measurement group_id="O3" value="-1.19" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 Hours Postdose (n=236, 233, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="0.16"/>
                    <measurement group_id="O2" value="-1.35" spread="0.16"/>
                    <measurement group_id="O3" value="-1.14" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 10 Hours Postdose (n=237,232,231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="0.16"/>
                    <measurement group_id="O2" value="-1.19" spread="0.16"/>
                    <measurement group_id="O3" value="-0.90" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 Hours Postdose (n=236, 233, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.16"/>
                    <measurement group_id="O2" value="-1.15" spread="0.16"/>
                    <measurement group_id="O3" value="-0.87" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Predose (n=237,234,233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.15"/>
                    <measurement group_id="O2" value="-0.81" spread="0.15"/>
                    <measurement group_id="O3" value="-0.45" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 6 Hours Postdose (n=237,233,231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="0.17"/>
                    <measurement group_id="O2" value="-1.59" spread="0.17"/>
                    <measurement group_id="O3" value="-1.16" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 12 Hours Postdose (n=235,233,232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="0.16"/>
                    <measurement group_id="O2" value="-1.59" spread="0.17"/>
                    <measurement group_id="O3" value="-0.77" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Improvement in Instantaneous Total Ocular Symptoms Scores (iTOSS) in Subjects With Baseline iTOSS ≥5.0</title>
        <description>Onset of improvement iTOSS was defined as the first assessment at which iTOSSS for active treatment demonstrated an improvement over placebo from baseline. TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval.</description>
        <time_frame>Baseline and up to 48 hours</time_frame>
        <population>In Subjects With Baseline iTOSS ≥5.0</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Onset of Improvement in Instantaneous Total Ocular Symptoms Scores (iTOSS) in Subjects With Baseline iTOSS ≥5.0</title>
          <description>Onset of improvement iTOSS was defined as the first assessment at which iTOSSS for active treatment demonstrated an improvement over placebo from baseline. TOSS is the sum of individual ocular symptoms of itching, tearing, and redness. Subjects assess each individual symptoms on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, TOSS ranges from 0-9 (with 0 representing an absence of symptoms and 9 reflecting more severe symptoms). Instantaneous TOSS symptom scores assess symptoms over the previous 10 minute time interval.</description>
          <population>In Subjects With Baseline iTOSS ≥5.0</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 4 Hours Postdose (n=149, 150, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.14"/>
                    <measurement group_id="O2" value="-0.57" spread="0.14"/>
                    <measurement group_id="O3" value="-0.53" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 6 Hours Postdose (n=149, 150, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.16"/>
                    <measurement group_id="O2" value="-0.83" spread="0.16"/>
                    <measurement group_id="O3" value="-0.75" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 8 Hours Postdose (n=148, 150, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.15"/>
                    <measurement group_id="O2" value="-0.97" spread="0.15"/>
                    <measurement group_id="O3" value="-0.72" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 10 Hours Postdose (n=149, 150, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="0.16"/>
                    <measurement group_id="O2" value="-0.79" spread="0.15"/>
                    <measurement group_id="O3" value="-0.69" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 Hours Postdose (n=149, 148, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.15"/>
                    <measurement group_id="O2" value="-0.83" spread="0.15"/>
                    <measurement group_id="O3" value="-0.49" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Predose (n=149, 149, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.15"/>
                    <measurement group_id="O2" value="-0.37" spread="0.15"/>
                    <measurement group_id="O3" value="-0.09" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 6 Hours Postdose (n=149, 150, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="0.16"/>
                    <measurement group_id="O2" value="-1.15" spread="0.16"/>
                    <measurement group_id="O3" value="-0.71" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 12 Hours Postdose (n=149, 149, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.16"/>
                    <measurement group_id="O2" value="-1.26" spread="0.16"/>
                    <measurement group_id="O3" value="-0.47" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximal Effect as Measured by Change From Baseline in the Average AM and PM Reflective Total Nasal Symptoms Scores (rTNSS)</title>
        <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day.</description>
        <time_frame>Week 0-2</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>80 mcg Ciclesonide</title>
            <description>80 mcg Ciclesonide once daily</description>
          </group>
          <group group_id="O2">
            <title>160 mcg Ciclesonide</title>
            <description>160 mcg Ciclesonide once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximal Effect as Measured by Change From Baseline in the Average AM and PM Reflective Total Nasal Symptoms Scores (rTNSS)</title>
          <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between Ciclesonide HFA and placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day.</description>
          <population>Intent to Treat Population</population>
          <units>days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="0.20"/>
                    <measurement group_id="O2" value="8" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>A treatment emergent adverse event is defined as an event with onset data occuring on or after the date of first dose of study medication. A subject with multiple events per system organ class or per preferred term was counted only once per system organ class.</desc>
      <group_list>
        <group group_id="E1">
          <title>80 mcg Ciclesonide</title>
          <description>80 mcg Ciclesonide once daily</description>
        </group>
        <group group_id="E2">
          <title>160 mcg Ciclesonide</title>
          <description>160 mcg Ciclesonide once daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="235"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site irritation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="235"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="235"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nasal discomort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="235"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nasal septum disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>This study was not designed or powered for a comparison of the 80mcg dose with the 160mcg dose therefore no statistical comparisons were planned between the two active groups. Publication references to 74 and 148mcg are equivalent to 80 and 160mcg</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

